Table 1. Patient and transplant characteristics.
| Characteristics | HRD | MUD | MSD | P |
|---|---|---|---|---|
| No. of patients | 124 | 140 | 181 | |
| Sex M/F | 90/34 | 81/59 | 101/80 | 0.008 |
| Median age, y (range) | 26 (14–57) | 28 (14–50) | 32 (14–59) | 0.01 |
| Primary diseases mye/lym/MDS |
68/52/4 | 59/64/7 | 88/79/13 | NS |
|
Disease status at HSCT CR/non-CR |
90/34 | 101/39 | 152/29 | 0.016 |
|
Source of stem cells PBSC/ PBSC+BM |
7/117 | 140/0 | 172/9 | < 0.001 |
|
HLA disparity matched/ mismatched |
4/120 | 101/39 | 181/0 | < 0.001 |
| ABO matched Y/N | 71/53 | 58/82 | 91/90 | 0.035 |
| Sex matched Y/N | 67/57 | 71/67 | 77/104 | NS |
| ATG/CD25 used※ Y/N | 110/14 | 138/2 | 11/170 | < 0.001 |
| TBI used Y/N | 77/47 | 88/52 | 99/82 | NS |
| Median MNCs, 108/kg (range) | 7.90 (3.09–13.32) | 7.54 (2.76–12.87) | 7.3 (3.43–13.47) | NS |
| Median CD34+ count, 106/kg (range) | 6.6 (1.64–13) | 7.05 (1.2–20.80) | 6.24 (0.67–18.26) | NS |
| PLT engraftment, d(range) | 15 (9–90) | 13 (9–49) | 12 (9–100) | 0.001 |
| WBC engraftment, d(range) | 13 (9–70) | 12 (9–40) | 11 (8–47) | < 0.001 |
| CMV viremia Y/N | 96/28 | 80/60 | 78/103 | < 0.001 |
| Acute GVHD Y/N | 72/52 | 73/67 | 93/88 | NS |
| Chronic GVHD Y/N | 25/99 | 20/120 | 34/147 | NS |
Abbreviations: M, male; F, female; mye, myelogenous diseases, including AML, AUL and CML; lym, lymphoid diseases, including ALL and NHL; CR, complete response; PBSC, peripheral blood stem cell; BM, bone marrow; TBI, total body irradiation; MNC, mononuclear cell; PLT: platelet; WBC: white blood cell; CMV, cytomegalovirus; Y, Yes; N, No.
*ATG (antithymocyte globulin) was given either as prophylaxis or for treatment of GVHD.